7 Hills Pharma is a clinical-stage immunotherapy company developing a platform of first-in-class, oral small molecules leveraging a unique mechanism of action to potentially improve the effectiveness of immuno-oncology therapeutics for solid tumors and vaccinations for infectious diseases.
Our lead molecule, 7HP349, is a first-in-concept integrin activator that stabilizes critical cell-cell interactions required to generate a productive antigen-specific immune response.
In preclinical models, 7HP349 improves the effectiveness of immune checkpoint inhibitors for cancer, as well as vaccines for influenza, COVID-19, and tuberculosis, among others. In our first-in-human Phase I clinical trial, 7HP349 demonstrated oral bioavailability and an excellent safety profile at exposures well exceeding therapeutic levels.
We are seeking partnerships with companies whose developmental immunotherapies might benefit from safely enhanced systemic immunogenicity.
Our lead molecule, 7HP349, is a first-in-concept integrin activator that stabilizes critical cell-cell interactions required to generate a productive antigen-specific immune response.
In preclinical models, 7HP349 improves the effectiveness of immune checkpoint inhibitors for cancer, as well as vaccines for influenza, COVID-19, and tuberculosis, among others. In our first-in-human Phase I clinical trial, 7HP349 demonstrated oral bioavailability and an excellent safety profile at exposures well exceeding therapeutic levels.
We are seeking partnerships with companies whose developmental immunotherapies might benefit from safely enhanced systemic immunogenicity.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Texas
Company HQ Country:
United States
Year Founded:
2016
Main Therapeutic Focus:
Lead Product in Development:
7HP349
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
